Cited by 138Genomics, phytochemicals, and oxidative stressUbiquitin and proteasome pathwaysNF-κB Signaling Pathways

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Cancer-Derived Mutations in KEAP1 Impair NRF2 Degradation but not Ubiquitination

Open access

Hast, Bridgid E., Cloer, Erica W., Goldfarb, Dennis, Li, Heng, Siesser, Priscila F., Yan, Feng, Walter, Vonn, Zheng, Ning, Hayes, D. Neil, Major, Michael B.·2014·Cancer Research

DOI 10.1158/0008-5472.can-13-1655PMC PMC3932503

Published version of a preprint

Open this paper in CoChat — free account

Abstract

NRF2 is a transcription factor that mediates stress responses. Oncogenic mutations in NRF2 localize to one of its two binding interfaces with KEAP1, an E3 ubiquitin ligase that promotes proteasome-dependent degradation of NRF2. Somatic mutations in KEAP1 occur commonly in human cancer, where KEAP1 may function as a tumor suppressor. These mutations distribute throughout the KEAP1 protein but little is known about their functional impact. In this study, we characterized 18 KEAP1 mutations defined in a lung squamous cell carcinoma tumor set. Four mutations behaved as wild-type KEAP1, thus are likely passenger events. R554Q, W544C, N469fs, P318fs, and G333C mutations attenuated binding and suppression of NRF2 activity. The remaining mutations exhibited hypomorphic suppression of NRF2, binding both NRF2 and CUL3. Proteomic analysis revealed that the R320Q, R470C, G423V, D422N, G186R, S243C, and V155F mutations augmented the binding of KEAP1 and NRF2. Intriguingly, these “super-binder” mutants exhibited reduced degradation of NRF2. Cell-based and in vitro biochemical analyses demonstrated that despite its inability to suppress NRF2 activity, the R320Q “superbinder” mutant maintained the ability to ubiquitinate NRF2. These data strengthen the genetic interactions between KEAP1 and NRF2 in cancer and provide new insight into KEAP1 mechanics. Cancer Res; 74(3); 808–17. ©2013 AACR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-13-1655

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Comprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Self-citation
The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1
Komatsu, M., Kurokawa, H., Waguri, S., Taguchi, K., Kobayashi, A., Ichimura, Y., Sou, Y.-S., Ueno, I., Sakamoto, A., Tong, K. I., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2021 · Cited by 2,288
Recognition and Processing of Ubiquitin-Protein Conjugates by the Proteasome
Finley, D. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.081507.101607 · Cited by 1,764
Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
Mitsuishi, Y., Taguchi, K., Kawatani, Y., Shibata, T., Nukiwa, T., Aburatani, H., Yamamoto, M., & Motohashi, H. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.016 · Cited by 1,395 · cited 1×
“Recent studies also establish a role for NRF2 in modulating anabolic pathways to suit the metabolic demands of cancer cell growth, effectively yielding an increase in cancer cell proliferation (6).”
Keap1 Is a Redox-Regulated Substrate Adaptor Protein for a Cul3-Dependent Ubiquitin Ligase Complex
Zhang, D. D., Lo, S., Cross, J. V., Templeton, D. J., & Hannink, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.24.10941-10953.2004 · Cited by 1,284
The Keap1-BTB Protein Is an Adaptor That Bridges Nrf2 to a Cul3-Based E3 Ligase: Oxidative Stress Sensing by a Cul3-Keap1 Ligase
Cullinan, S. B., Gordan, J. D., Jin, J., Harper, J. W., & Diehl, J. A. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.19.8477-8486.2004 · Cited by 986
NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer
Hayes, J. D., & McMahon, M. J. (2009) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2008.12.008 · Cited by 870
Keap1 Recruits Neh2 through Binding to ETGE and DLG Motifs: Characterization of the Two-Site Molecular Recognition Model
Tong, K. I., Katoh, Y., Kusunoki, H., Itoh, K., Tanaka, T., & Yamamoto, M. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.8.2887-2900.2006 · Cited by 759 · cited 1×
“Regardless of tissue origin, nearly all somatic mutations within NRF2 fall to either the ETGE or the DLG motif, two regulatory short amino acid sequences within NRF2 that contact KEAP1 (3).”
Identification of Targetable FGFR Gene Fusions in Diverse Cancers
Wu, Y.-M., Su, F., Sundaram, S. K., Khazanov, N. A., Ateeq, B., Cao, X., Lonigro, R. J., Vats, P., Wang, R., Lin, S., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0050 · Cited by 759
BTB Protein Keap1 Targets Antioxidant Transcription Factor Nrf2 for Ubiquitination by the Cullin 3-Roc1 Ligase
Furukawa, M., & Xiong, Y. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.25.1.162-171.2005 · Cited by 759

Show all 45 references

Sorted by citations

A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles
Subramanian, A., Narayan, R., Corsello, S. M., Peck, D. D., Natoli, T. E., Lu, X., Gould, J., Davis, J. F., Tubelli, A. A., Asiedu, J. K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.049 · Cited by 3,515
The Molecular Mechanisms Regulating the KEAP1-NRF2 Pathway
Baird, L., & Yamamoto, M. P. (2020) · Molecular and Cellular Biology · doi:10.1128/mcb.00099-20 · Cited by 1,671
Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas
Cancer Genome Atlas Research Network, Campbell, J. D., Alexandrov, A., Kim, J., Wala, J., Berger, A. H., Pedamallu, C. S., Shukla, S. A., Guo, G., Brooks, A. N., et al. (2016) · Nature Genetics · doi:10.1038/ng.3564 · Cited by 1,200
Molecular basis of the Keap1–Nrf2 system
Suzuki, T., & Yamamoto, M. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.06.006 · Cited by 995
Opportunities and challenges of radiotherapy for treating cancer
Schaue, D., & McBride, W. H. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.120 · Cited by 784
The KEAP1-NRF2 pathway: Targets for therapy and role in cancer
Adinolfi, S., Patinen, T., Deen, A. J., Pitkänen, S., Härkönen, J., Kansanen, E., Küblbeck, J., & Levonen, A. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102726 · Cited by 326
The Role of Nrf2 Activity in Cancer Development and Progression
Zimța, A., Cenariu, D., Irimie, A., Magdo, L., Nabavi, S. M., Atanasov, A. G., & Berindan‐Neagoe, I. (2019) · Cancers · doi:10.3390/cancers11111755 · Cited by 309
Beyond repression of Nrf2: An update on Keap1
Kopacz, A., Klóska, D., Forman, H. J., Józkowicz, A., & Grochot‐Przeczek, A. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.03.023 · Cited by 269
Thirty years of NRF2: advances and therapeutic challenges.
Zhang, D. D. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01145-0 · Cited by 282
Characterizing the molecular regulation of inhibitory immune checkpoints with multimodal single-cell screens
Papalexi, E., Mimitou, E. P., Butler, A. W., Foster, S., Bracken, B., Mauck, W. M., Wessels, H.-H., Hao, Y., Yeung, B. Z., Smibert, P., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00778-2 · Cited by 237
NRF2 activation promotes the recurrence of dormant tumour cells through regulation of redox and nucleotide metabolism
Fox, D. B., Garcia, N. M. G., McKinney, B. J., Lupo, R., Noteware, L. C., Newcomb, R., Liu, J., Locasale, J. W., Hirschey, M. D., & Alvarez, J. V. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0191-z · Cited by 214
High-throughput phenotyping of lung cancer somatic mutations
Berger, A. H., Brooks, A. N., Wu, X., Shrestha, Y., Chouinard, C., Piccioni, F., Bagul, M., Kamburov, A., Imielinski, M., Hogstrom, L., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.022 · Cited by 192
NRF2: KEAPing Tumors Protected
Pillai, R., Hayashi, M., Zavitsanou, A.-M., & Papagiannakopoulos, T. Y. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0922 · Cited by 196
NRF2 Activation in Cancer: From DNA to Protein
Cloer, E. W., Goldfarb, D., Schrank, T. P., Weissman, B. E., & Major, M. B. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2723 · Cited by 182
Self-citation
Dysregulation of Nrf2 in Hepatocellular Carcinoma: Role in Cancer Progression and Chemoresistance
Raghunath, A., Sundarraj, K., Arfuso, F., Sethi, G., & Perumal, E. (2018) · Cancers · doi:10.3390/cancers10120481 · Cited by 187
Potential Applications of NRF2 Inhibitors in Cancer Therapy
Panieri, E., & Saso, L. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/8592348 · Cited by 189
Glutathione as a Marker for Human Disease
Teskey, G., Abrahem, R., Cao, R., Gyurjian, K., Islamoglu, H., Lucero, M., Martinez, A., Paredes, E., Salaiz, O., Robinson, B., et al. (2018) · Advances in clinical chemistry · doi:10.1016/bs.acc.2018.07.004 · Cited by 188
A genetic basis for the variation in the vulnerability of cancer to DNA damage
Yard, B. D., Adams, D., Chie, E. K., Tamayo, P., Battaglia, J., Gopal, P., Rogacki, K. R., Pearson, B. E., Phillips, J. G., Raymond, D. P., et al. (2016) · Nature Communications · doi:10.1038/ncomms11428 · Cited by 188
Monitoring Keap1–Nrf2 interactions in single live cells
Baird, L., Swift, S., Llères, D., & Dinkova‐Kostova, A. T. (2014) · Biotechnology Advances · doi:10.1016/j.biotechadv.2014.03.004 · Cited by 179
NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes
Singh, A., Daemen, A., Nickles, D., Jeon, S., Foreman, O., Sudini, K. R., Gnad, F., Lajoie, S., Gour, N., Mitzner, W., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1985 · Cited by 170
KEAP1/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition
Binkley, M. S., Jeon, Y.-J., Nesselbush, M. C., Moding, E. J., Nabet, B. Y., Almanza, D., Kunder, C. A., Stehr, H., Yoo, C. H., Rhee, S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0282 · Cited by 165
Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape
Faruki, H., Mayhew, G. M., Serody, J. S., Hayes, D. N., Perou, C. M., & Lai-Goldman, M. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.03.010 · Cited by 159
Self-citation
KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance
Zavitsanou, A., Pillai, R., Yuan, H., Wu, W., Bartnicki, E., Karakousi, T. R., Rajalingam, S., Herrera, A. M., Karatza, A., Rashidfarrokhi, A., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113295 · Cited by 157
Degrons in cancer
Mészáros, B., Kumar, M., Gibson, T. J., Uyar, B., & Dosztányi, Z. (2017) · Science Signaling · doi:10.1126/scisignal.aak9982 · Cited by 147
A catalogue of somatic NRF2 gain-of-function mutations in cancer
Kerins, M. J., & Ooi, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-31281-0 · Cited by 140
Cysteine dioxygenase 1 is a metabolic liability for non-small cell lung cancer
Kang, Y. P., Torrente, L., Falzone, A., Elkins, C. M., Liu, M., Asara, J. M., Dibble, C. C., & DeNicola, G. M. (2019) · eLife · doi:10.7554/elife.45572 · Cited by 129
Cross-cancer profiling of molecular alterations within the human autophagy interaction network
Lebovitz, C. B., Robertson, A. G., Goya, R., Jones, S. J. M., Morin, R. D., Marra, M. A., & Gorski, S. M. (2015) · Autophagy · doi:10.1080/15548627.2015.1067362 · Cited by 136
Exome-Scale Discovery of Hotspot Mutation Regions in Human Cancer Using 3D Protein Structure
Tokheim, C. J., Bhattacharya, R., Niknafs, N., Gygax, D. M., Kim, R., Ryan, M. T., Masica, D. L., & Karchin, R. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3190 · Cited by 123
NRF2 activates a partial epithelial-mesenchymal transition and is maximally present in a hybrid epithelial/mesenchymal phenotype
Bocci, F., Tripathi, S. C., Mercedes, S. A. V., George, J. T., Casabar, J. P., Wong, P. K., Hanash, S., Levine, H., Onuchic, J. N., & Jolly, M. K. (2019) · Integrative Biology · doi:10.1093/intbio/zyz021 · Cited by 132
Application of Mass Spectrometry Profiling to Establish Brusatol as an Inhibitor of Global Protein Synthesis
Vartanian, S., Ma, T. P., Lee, J., Haverty, P. M., Kirkpatrick, D. S., Yu, K., & Stokoe, D. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m115.055509 · Cited by 118
The role of natural products in revealing NRF2 function
Zhang, D. D., & Chapman, E. (2020) · Natural Product Reports · doi:10.1039/c9np00061e · Cited by 123
A clinical drug library screen identifies clobetasol propionate as an NRF2 inhibitor with potential therapeutic efficacy in KEAP1 mutant lung cancer
Choi, E.-J., Jung, B.-J., Lee, S.-H., Yoo, H.-S., Shin, E.-A., Ko, H., Chang, S., Kim, S.-Y., & Jeon, S.-M. (2017) · Oncogene · doi:10.1038/onc.2017.153 · Cited by 115
Glycosylation of KEAP1 links nutrient sensing to redox stress signaling
Chen, P., Smith, T. J., Wu, J., Siesser, P. F., Bisnett, B. J., Khan, F., Hogue, M., Soderblom, E. J., Tang, F., Marks, J. R., et al. (2017) · The EMBO Journal · doi:10.15252/embj.201696113 · Cited by 105
Self-citation
Peroxiredoxin Involvement in the Initiation and Progression of Human Cancer
Hampton, M. B., Vick, K. A., Skoko, J., & Neumann, C. A. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7422 · Cited by 103
Kelch-like ECH-associated protein 1 (KEAP1) differentially regulates nuclear factor erythroid-2–related factors 1 and 2 (NRF1 and NRF2)
Tian, W., de la Vega, M. R., Schmidlin, C. J., Ooi, A., & Zhang, D. D. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.000428 · Cited by 101
Five years left – How are the EU member states contributing to the 20% target for EU's renewable energy consumption; the role of woody biomass
Proskurina, S., Sikkema, R., Heinimö, J., & Vakkilainen, E. K. (2016) · Biomass and Bioenergy · doi:10.1016/j.biombioe.2016.09.016 · Cited by 97
Regulating Nrf2 activity: ubiquitin ligases and signaling molecules in redox homeostasis
Hayes, J. D., Naidu, S. D., & Dinkova‐Kostova, A. T. (2025) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2024.12.010 · Cited by 103
Cytoprotection “gone astray’’: Nrf2 and its role in cancer
Schäfer, H., Geismann, C., Arlt, A., & Sebens, S. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s36624 · Cited by 93
NRF2 and the Ambiguous Consequences of Its Activation during Initiation and the Subsequent Stages of Tumourigenesis
Robertson, H., Dinkova‐Kostova, A. T., & Hayes, J. D. (2020) · Cancers · doi:10.3390/cancers12123609 · Cited by 89
Identification and Characterization of MCM3 as a Kelch-like ECH-associated Protein 1 (KEAP1) Substrate
Mulvaney, K. M., Matson, J. P., Siesser, P. F., Tamir, T. Y., Goldfarb, D., Jacobs, T. M., Cloer, E. W., Harrison, J. S., Vaziri, C., Cook, J. G., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.729418 · Cited by 82
Self-citation
RNA-binding motif protein 47 inhibits Nrf2 activity to suppress tumor growth in lung adenocarcinoma
Sakurai, T., Isogaya, K., Sakai, S., Morikawa, M., Morishita, Y., Ehata, S., Miyazono, K., & Koinuma, D. (2016) · Oncogene · doi:10.1038/onc.2016.35 · Cited by 82
Targeting the NRF2/KEAP1 pathway in cervical and endometrial cancers
Tossetta, G., & Marzioni, D. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175503 · Cited by 81
The Regulation of NRF2 by Nutrient-Responsive Signaling and Its Role in Anabolic Cancer Metabolism
Lee, S. B., Sellers, B. N., & DeNicola, G. M. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7356 · Cited by 78
Keap1 mutation renders lung adenocarcinomas dependent on Slc33a1
Romero, R., Rivera, F. J. S., Westcott, P. M. K., Mercer, K. L., Bhutkar, A. J., Muir, A., González-Robles, T. J., Rodríguez, S. L., Liao, L. Z., Ng, S. R., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0071-1 · Cited by 76
Regulation of cell signaling pathways by dietary agents for cancer prevention and treatment
Pandey, M. K., Gupta, S. C., Nabavizadeh, A., & Aggarwal, B. B. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.07.002 · Cited by 73
Cancer Cell Growth Is Differentially Affected by Constitutive Activation of NRF2 by KEAP1 Deletion and Pharmacological Activation of NRF2 by the Synthetic Triterpenoid, RTA 405
Probst, B., Lyndsey, M., Isaac, T., Wigley, W. C., & Ferguson, D. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135257 · Cited by 70
The Pleiotropic Role of the KEAP1/NRF2 Pathway in Cancer
Wu, W., & Papagiannakopoulos, T. Y. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055627 · Cited by 70
Emerging Substrate Proteins of Kelch-like ECH Associated Protein 1 (Keap1) and Potential Challenges for the Development of Small-Molecule Inhibitors of the Keap1-Nuclear Factor Erythroid 2‑Related Factor 2 (Nrf2) Protein–Protein Interaction
Zhang, Y., Shi, Z., Zhou, Y., Xiao, Q., Wang, H., & Peng, Y. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01865 · Cited by 67
p62-Dependent Phase Separation of Patient-Derived KEAP1 Mutations and NRF2
Cloer, E. W., Siesser, P. F., Cousins, E. M., Goldfarb, D., Mowrey, D. D., Harrison, J. S., Weir, S., Dokholyan, N. V., & Major, M. B. (2018) · Molecular and Cellular Biology · doi:10.1128/mcb.00644-17 · Cited by 69
Self-citation
Aldo-keto reductases are biomarkers of NRF2 activity and are co-ordinately overexpressed in non-small cell lung cancer
MacLeod, A. K., Acosta-Jimenez, L., Coates, P. J., McMahon, M. J., Carey, F. A., Honda, T., Henderson, C. J., & Wolf, C. R. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.363 · Cited by 65
Dimethyl fumarate potentiates oncolytic virotherapy through NF-κB inhibition
Selman, M., Ou, P., Rousso, C., Bergeron, A., Krishnan, R., Pikor, L. A., Chen, A., Keller, B. A., Ilkow, C. S., Bell, J. C., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao1613 · Cited by 68
Substrate Trapping Proteomics Reveals Targets of the βTrCP2/FBXW11 Ubiquitin Ligase
Kim, T. Y., Siesser, P. F., Rossman, K. L., Goldfarb, D., MacKinnon, K. M., Yan, F., Yi, X., MacCoss, M. J., Moon, R. T., Der, C. J., et al. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00857-14 · Cited by 64
Self-citation
Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
Osman, A. A., Arslan, E., Bartels, M. D., Michikawa, C., Lindemann, A., Tomczak, K. J., Yu, W., Sandulache, V. C., Ma, W., Shen, L., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2747 · Cited by 63
Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer
Tian, Y., Wu, K., Liu, Q., Han, N., Zhang, L., Chu, Q., & Chen, Y. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0311-0 · Cited by 59
Chemical and genetic control of IFNγ‐induced MHCII expression
Wijdeven, R. H. M., van Luijn, M. M., Wierenga‐Wolf, A. F., Akkermans, J. J. L. L., van den Elsen, P. J., Hintzen, R. Q., & Neefjes, J. (2018) · EMBO Reports · doi:10.15252/embr.201745553 · Cited by 59
CRL3s: The BTB-CUL3-RING E3 Ubiquitin Ligases
Wang, P., Song, J., & Ye, D. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-1025-0_13 · Cited by 53
Genome-wide CRISPR screens of oral squamous cell carcinoma reveal fitness genes in the Hippo pathway
Chai, A. W. Y., Yee, P. S., Price, S., Yee, S. M., Lee, H. M., Tiong, V. K., Gonçalves, E., Behan, F. M., Bateson, J., Gilbert, J. G. R., et al. (2020) · eLife · doi:10.7554/elife.57761 · Cited by 55
Nrf2, the master redox switch: The Achilles' heel of ovarian cancer?
van der Wijst, M. G. P., Brown, R. E., & Rots, M. G. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.09.004 · Cited by 54
Targeted therapy of esophageal squamous cell carcinoma: the NRF2 signaling pathway as target
Ma, S., Paiboonrungruan, C., Yan, T., Williams, K. P., Major, M. B., & Chen, X. L. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13681 · Cited by 54
Self-citation
Keap1–Nrf2 pathway: A promising target towards lung cancer prevention and therapeutics
Tong, Y., Zhang, B., Fan, Y., & Lin, N. (2015) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2015.09.002 · Cited by 51
NADPH Oxidase 4 (NOX4) in Cancer: Linking Redox Signals to Oncogenic Metabolic Adaptation
Szántó, I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052702 · Cited by 52
The oncoprotein HBXIP competitively binds KEAP1 to activate NRF2 and enhance breast cancer cell growth and metastasis
Zhou, X., Zhu, C.-Y., Wu, Z., Guo, X., & Zou, W. (2019) · Oncogene · doi:10.1038/s41388-019-0698-5 · Cited by 50
Comparative structural and evolutionary analyses predict functional sites in the artemisinin resistance malaria protein K13
Coppée, R., Jeffares, D. C., Miteva, M. A., Sabbagh, A., & Clain, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-47034-6 · Cited by 53
Distinct Nrf2 Signaling Thresholds Mediate Lung Tumor Initiation and Progression
DeBlasi, J. M., Falzone, A., Caldwell, S., Prieto-Farigua, N., Prigge, J. R., Schmidt, E. E., Chio, I. I. C., Karreth, F. A., & DeNicola, G. M. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3848 · Cited by 49
“Both Keap1R554Q and Nrf2D29H mutations 219 prevent Keap1-mediated ubiquitination of Nrf2, allowing for constitutive expression of Nrf2 and 220 transcription of Nrf2 target genes (46, 47).”
An Aggressive Subtype of Stage I Lung Adenocarcinoma with Molecular and Prognostic Characteristics Typical of Advanced Lung Cancers
Dama, E., Melocchi, V., Dezi, F., Pirroni, S., Carletti, R. M., Brambilla, D., Bertalot, G., Casiraghi, M., Maisonneuve, P., Barberis, M. C. P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3005 · Cited by 48
Understanding the Emerging Link Between Circadian Rhythm, Nrf2 Pathway, and Breast Cancer to Overcome Drug Resistance
Bevinakoppamath, S., Ramachandra, S. C., Yadav, A. K., Basavaraj, V., Vishwanath, P., & Prashant, A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.719631 · Cited by 42
Curcumin induces p53-independent inactivation of Nrf2 during oxidative stress–induced apoptosis
Méndez-García, L., Castillo, M. M., Villegas‐Sepúlveda, N., Orozco, L., & Córdova, E. J. (2019) · Human & Experimental Toxicology · doi:10.1177/0960327119845035 · Cited by 42
IKKα inactivation promotes Kras-initiated lung adenocarcinoma development through disrupting major redox regulatory pathways
Song, N., Zhu, F., Wang, Z., Willette‐Brown, J., Xi, S., Sun, Z., Su, L., Wu, X., Ma, B., Nussinov, R., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717520115 · Cited by 39
Erratum: Aldo-keto reductases are biomarkers of NRF2 activity and are co-ordinately overexpressed in non-small cell lung cancer
MacLeod, A. K., Acosta-Jimenez, L., Coates, P. J., McMahon, M. J., Carey, F. A., Honda, T., Hayes, J. D., Henderson, C. J., & Wolf, C. R. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.80 · Cited by 36
The mechanistic insights of the antioxidant Keap1-Nrf2 pathway in oncogenesis: a deadly scenario
Mukherjee, A. G., & Gopalakrishnan, A. V. (2023) · Medical Oncology · doi:10.1007/s12032-023-02124-4 · Cited by 33
Oncogenic KEAP1 mutations activate TRAF2-NFκB signaling to prevent apoptosis in lung cancer cells
Deen, A. J., Adinolfi, S., Härkönen, J., Patinen, T., Liu, X., Laitinen, T., Takabe, P., Kainulainen, K., Pasonen-Seppänen, S., Gawriyski, L. M., et al. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103031 · Cited by 27
Regulation of Cell Proliferation and Nrf2-Mediated Antioxidant Defense: Conservation of Keap1 Cysteines and Nrf2 Binding Site in the Context of the Evolution of KLHL Family
Shilovsky, G. A., & Dibrova, D. V. (2023) · Life · doi:10.3390/life13041045 · Cited by 27
Engineering a genetically encoded competitive inhibitor of the KEAP1–NRF2 interaction via structure-based design and phage display
Guntas, G., Lewis, S. M., Mulvaney, K. M., Cloer, E. W., Tripathy, A., Lane, T. R., Major, M. B., & Kuhlman, B. A. (2015) · Protein Engineering Design and Selection · doi:10.1093/protein/gzv055 · Cited by 26
Self-citation
Molecular Targets of Oxidative Stress: Focus on Nuclear Factor Erythroid 2–Related Factor 2 Function in Leukemia and Other Cancers
Hasan, S. K., Jayakumar, S., Barroso, E. E., Jha, A., Catalano, G., Sandur, S. K., & Noguera, N. I. (2025) · Cells · doi:10.3390/cells14100713 · Cited by 31
ERBB3 and IGF1R Signaling Are Required for Nrf2-Dependent Growth in KEAP1-Mutant Lung Cancer
Vartanian, S., Lee, J., Klijn, C. N., Gnad, F., Bagniewska, M., Schaefer, G., Zhang, D., Tan, J., Watson, S. A., Liu, L., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2086 · Cited by 25
Simultaneous K-ras activation and Keap1 deletion cause atrophy of pancreatic parenchyma
Hamada, S., Shimosegawa, T., Taguchi, K., Nabeshima, T., Yamamoto, M. P., & Masamune, A. (2017) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00228.2017 · Cited by 24
MutationAligner: a resource of recurrent mutation hotspots in protein domains in cancer
Gauthier, N. P., Reznik, E., Gao, J., Sümer, S. O., Schultz, N. D., Sander, C., & Miller, M. L. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1132 · Cited by 24
KEAP1 Is Required for Artesunate Anticancer Activity in Non-Small-Cell Lung Cancer
Hill, K. S., McDowell, A., McCorkle, J. R., Schuler, E. E., Ellingson, S. R., Plattner, R., & Kolesar, J. (2021) · Cancers · doi:10.3390/cancers13081885 · Cited by 23
Metabolic reprogramming by histone deacetylase inhibition preferentially targets NRF2-activated tumors
Karagiannis, D., Wu, W., Li, A. M., Hayashi, M., Chen, X., Yip, M., Mangipudy, V. S., Xu, X., Rivera, F. J. S., Soto‐Feliciano, Y. M., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113629 · Cited by 26
Retracted: NQO1 promotes an aggressive phenotype in hepatocellular carcinoma via amplifying ERK‐NRF2 signaling
Yang, Y., Zheng, J., Wang, M., Zhang, J., Tao, T., Wang, Z., Yuan, S., Liu, L., Zhu, P., Gu, F., et al. (2020) · Cancer Science · doi:10.1111/cas.14744 · Cited by 22
Retracted
ARD1 stabilizes NRF2 through direct interaction and promotes colon cancer progression
Fang, X., Lee, Y., Jang, J., Kim, S., Kim, S. H., Kim, D., Na, H., Kim, K.-O., Baek, J., & Surh, Y. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121217 · Cited by 22
Nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) in non-small cell lung cancer
Zeng, Z., Wang, Z., Li, Y., Ye, D., Zeng, J., Hu, J., Chen, P.-F., Xiao, J., Zou, J., & Li, Z. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117325 · Cited by 22
Bicaudal D1 impairs autophagosome maturation in chronic obstructive pulmonary disease
Mercado, N., Colley, T., Baker, J. R., Vuppusetty, C., Kono, Y., Clarke, C., Tooze, S. A., Johansen, T., & Barnes, P. J. (2019) · FASEB BioAdvances · doi:10.1096/fba.2018-00055 · Cited by 21
Gene Expression Subtype Predicts Nodal Metastasis and Survival in Human Papillomavirus–Negative Head and Neck Cancer
Zevallos, J. P., Mazul, A. L., Walter, V., & Hayes, D. N. (2018) · The Laryngoscope · doi:10.1002/lary.27340 · Cited by 20
Self-citation
Downregulation of indolethylamine N‐methyltransferase is an early event in the rat hepatocarcinogenesis and is associated with poor prognosis in hepatocellular carcinoma patients
López‐Torres, C. D., Torres‐Mena, J. E., Castro‐Gil, M. P., Villa‐Treviño, S., Arellanes‐Robledo, J., del Pozo‐Yauner, L., & Pérez‐Carreón, J. I. (2022) · The Journal of Gene Medicine · doi:10.1002/jgm.3439 · Cited by 21
The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous Melanoma
Zhao, X., Little, P., Hoyle, A. P., Pegna, G. J., Hayward, M. C., Ivanova, A., Parker, J. S., Marron, D. L., Soloway, M. G., Jo, H., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2018.00584 · Cited by 20
Self-citation
Understanding serine and glycine metabolism in cancer: a path towards precision medicine to improve patient’s outcomes
Sánchez‐Castillo, A., & Kampen, K. R. (2024) · Discover Oncology · doi:10.1007/s12672-024-01544-6 · Cited by 18
Association of single-nucleotide polymorphisms of the KEAP1 gene with the risk of various human diseases and its functional impact using in silico analysis
Umapathy, D., Balashanmugam, P., Sireesh, D., Bhakkiyalakshmi, E., & Ramkumar, K. M. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.10.003 · Cited by 15
The NRF2 transcriptional target NQO1 has low mRNA levels in TP53-mutated endometrial carcinomas
Beinse, G., Just, P., Rance, B., Izac, B., Letourneur, F., Saidu, N. E. B., Chouzenoux, S., Nicco, C., Goldwasser, F., Pasmant, É., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0214416 · Cited by 17
The Complex Roles of Redox and Antioxidant Biology in CancerPreprint
Hayashi, M., Okazaki, K., Papgiannakopoulos, T., & Motohashi, H. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041546 · Cited by 16
Correlation of alterations in the KEAP1 / CUL3 / NFE2L2 pathway with radiation failure in larynx squamous cell carcinoma
Sheth, S. H., Farquhar, D. R., Schrank, T. P., Stepp, W. H., Mazul, A. L., Hayward, M. C., Lenze, N. R., Little, P., Jo, H., Major, M. B., et al. (2021) · Laryngoscope Investigative Otolaryngology · doi:10.1002/lio2.588 · Cited by 15
Self-citation
NRF2-Driven KEAP1 Transcription in Human Lung Cancer
Tian, Y., Liu, Q., Yu, S., Chu, Q., Chen, Y., Wu, K., & Wang, L. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0108 · Cited by 15
NRF2 assessment in discarded liver allografts: A role in allograft function and salvage
Ahmed, O., Xu, M., Zhou, F., Wein, A. N., Upadhya, G. A., Li, Y., Wong, B. W., Lin, Y., O’Farrelly, C., & Chapman, W. C. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16789 · Cited by 15
Different Inhibition of Nrf2 by Two Keap1 Isoforms α and β to Shape Malignant Behaviour of Human Hepatocellular Carcinoma
Chen, F., Xiao, M., Feng, J., Wufuer, R., Liu, K., Hu, S., & Zhang, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810342 · Cited by 13
Unique and overlapping roles of NRF2 and NRF1 in transcriptional regulation
Sekine, H., & Motohashi, H. (2023) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.23-106 · Cited by 14
KEAP1 Cancer Mutants: A Large-Scale Molecular Dynamics Study of Protein Stability
Wilson, C. J., Chang, M., Karttunen, M., & Choy, W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105408 · Cited by 12
A Naturally-Occurring Dominant-Negative Inhibitor of Keap1 Competitively against Its Negative Regulation of Nrf2
Qiu, L., Wang, M., Zhu, Y., Xiang, Y., & Zhang, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082150 · Cited by 12
Suppression of NRF2-dependent cancer growth by a covalent allosteric molecular gluePreprint
Roy, N., Wyseure, T. L., Lo, I., Metzger, J., Eissler, C. L., Bernard, S. M., Bok, I., Snead, A. N., Parker, A., Green, J. C., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.04.616592 · Cited by 12
Self-citation
Nrf2 protein in melanoma progression, as a new means of treatment
Feng, Q., Xu, X., & Zhang, S. (2023) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.13137 · Cited by 12
The lncRNA DAMER selectively guides m6A-dependent regulation of ATF4 and asparagine metabolism under nutrient stress in cancer
Tao, T., Feng, X., Yang, Y., Liu, B., Liang, J., Chen, Z., Wang, S., Zhao, J., Yang, X., Huo, L., et al. (2026) · Nature Cell Biology · doi:10.1038/s41556-026-01905-z · Cited by 11

Authors: Hast, B. E., Cloer, E. W., Goldfarb, D., Li, H., Siesser, P. F., Yan, F., Walter, V., Zheng, N., Hayes, D. N., & Major, M. B.
Affiliations: University of North Carolina at Chapel Hill (US)
Corresponding author: Major, Michael B.
ORCID: Goldfarb, Dennis
Siesser, Priscila F.
Yan, Feng
Walter, Vonn
Zheng, Ning
Hayes, D. Neil
Major, Michael B.
Venue: Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2014-02-01
Volume: 74
Issue: 3
Pages: 808-817
ISSN: 0008-5472 (ISSN-L)
1538-7445
DOI: 10.1158/0008-5472.can-13-1655
PMC: PMC3932503
OpenAlex: W2164442171
Cited by: 138
References: 45
Citations by year: 2026: 6 · 2025: 6 · 2024: 10 · 2023: 16 · 2022: 7 · 2021: 7 · 2020: 18 · 2019: 15 · 2018: 13 · 2017: 12 · 2016: 12 · 2015: 11 · 2014: 5
FWCI: 4.18
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Cancer Research (publishedVersion, public-domain)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion, public-domain)
UNC Libraries
Funders: Howard Hughes Medical Institute
Golfers Against Cancer
National Institutes of Health (1dp2od007149-01)
National Cancer Institute (U24CA143848, T32-CA09475, T32CA009475, T32CA071341)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics, phytochemicals, and oxidative stress
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
Keywords: Keap1, Nrf2, somatic mutations, lung squamous cell carcinoma, E3 ubiquitin ligase, proteasomal degradation, ubiquitination, protein-protein binding, CUL3, tumor suppressor, passenger mutations
MeSH terms: Kelch-Like ECH-Associated Protein 1, Humans, Models, Molecular, Mutation, Neoplasms, Protein Binding, Protein Conformation, Cell Line, Tumor, Intracellular Signaling Peptides and Proteins, NF-E2-Related Factor 2, Ubiquitination, Protein Multimerization, Proteolysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cancer-Derived Mutations in KEAP1 Impair NRF2 Degradation but not Ubiquitination

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks